Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?

Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, Schwaiger M, Scheidhauer K.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2005-13. doi: 10.1007/s00259-011-1875-0. Epub 2011 Jul 27.

PMID:
21792572
2.

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72. doi: 10.1007/s00259-012-2286-6. Epub 2012 Nov 14.

PMID:
23151915
3.

Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging.

Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A.

Nucl Med Commun. 2014 Jun;35(6):613-9. doi: 10.1097/MNM.0000000000000106.

PMID:
24686250
4.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

5.

Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.

Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.

Invest Radiol. 2013 May;48(5):273-9. doi: 10.1097/RLI.0b013e3182871a7f.

PMID:
23493121
6.

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.

J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30.

7.

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A.

Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52. doi: 10.1007/s00259-008-0944-5. Epub 2008 Sep 20.

PMID:
18807033
8.

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.

PMID:
23291643
9.

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26. Epub 2007 May 23.

PMID:
17520251
10.

Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

PMID:
22918768
11.

Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):501-11. doi: 10.1007/s00259-011-2003-x. Epub 2011 Dec 20.

PMID:
22183108
12.

64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.

Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, Oturai P, Loft A, Hag AM, Kjær A.

J Nucl Med. 2015 Dec;56(12):1895-900. doi: 10.2967/jnumed.115.161216. Epub 2015 Oct 1.

13.

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82. doi: 10.1007/s00259-011-1935-5. Epub 2011 Sep 17.

PMID:
21927931
14.

Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.

Müssig K, Oksüz MO, Dudziak K, Ueberberg B, Wehrmann M, Horger M, Schulz S, Häring HU, Pfannenberg C, Bares R, Gallwitz B, Petersenn S.

Horm Metab Res. 2010 Jul;42(8):599-606. doi: 10.1055/s-0030-1253354. Epub 2010 Apr 26.

PMID:
20422506
15.

Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.

Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2014-20. doi: 10.1007/s00259-016-3421-6. Epub 2016 Jun 13.

PMID:
27293206
16.

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.

J Nucl Med. 2009 Aug;50(8):1214-21. doi: 10.2967/jnumed.108.060236. Epub 2009 Jul 17.

17.

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):460-6. Epub 2006 Jan 17.

PMID:
16437218
18.

Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.

J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22.

PMID:
27660147
19.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.

J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18.

20.

Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.

Eur Radiol. 2011 Nov;21(11):2408-16. doi: 10.1007/s00330-011-2199-y. Epub 2011 Jul 13.

PMID:
21750886

Supplemental Content

Support Center